S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Dicerna Pharmaceuticals Stock Forecast, Price & News

-0.01 (-0.03%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
11.10 million shs
Average Volume
1.14 million shs
Market Capitalization
$2.96 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Dicerna Pharmaceuticals logo

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.


Dicerna Pharmaceuticals (NASDAQ:DRNA) Sees Strong Trading Volume
November 19, 2021 |  americanbankingnews.com
Dicerna Pharmaceuticals (NASDAQ:DRNA) Shares Gap Up to $21.28
November 18, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$164.31 million
Book Value
$1.38 per share


Net Income
$-112.75 million
Pretax Margin




Free Float
Market Cap
$2.96 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.20 out of 5 stars

Medical Sector

384th out of 1,391 stocks

Pharmaceutical Preparations Industry

175th out of 669 stocks

Analyst Opinion: 2.1Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

Is Dicerna Pharmaceuticals a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Dicerna Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DRNA, but not buy additional shares or sell existing shares.
View analyst ratings for Dicerna Pharmaceuticals
or view top-rated stocks.

How has Dicerna Pharmaceuticals' stock price been impacted by Coronavirus?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DRNA shares have increased by 125.1% and is now trading at $37.99.
View which stocks have been most impacted by COVID-19

Are investors shorting Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 2,880,000 shares, a decrease of 32.4% from the October 31st total of 4,260,000 shares. Based on an average daily volume of 1,610,000 shares, the short-interest ratio is currently 1.8 days. Approximately 4.2% of the shares of the company are sold short.
View Dicerna Pharmaceuticals' Short Interest

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Dicerna Pharmaceuticals

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.19. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%. During the same quarter in the prior year, the company posted ($0.29) EPS.
View Dicerna Pharmaceuticals' earnings history

What price target have analysts set for DRNA?

11 brokers have issued 1 year price objectives for Dicerna Pharmaceuticals' stock. Their forecasts range from $25.00 to $47.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $34.06 in the next twelve months. This suggests that the stock has a possible downside of 10.4%.
View analysts' price targets for Dicerna Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:

What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?

35 employees have rated Dicerna Pharmaceuticals CEO Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among Dicerna Pharmaceuticals' employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (9.73%), BlackRock Inc. (7.41%), Morgan Stanley (2.23%), Assenagon Asset Management S.A. (1.74%), Maverick Capital Ltd. (1.68%) and Polar Capital Holdings Plc (1.67%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, Karen Blasing, Ling Zeng, Marc D Kozin, Peter Kolchinsky, Regina M Paglia, Robert D Ciappenelli, Shreeram Aradhye and Stan Klimoff.
View institutional ownership trends for Dicerna Pharmaceuticals

Which institutional investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Eagle Asset Management Inc., Sumitomo Mitsui Trust Holdings Inc., Emerald Mutual Fund Advisers Trust, UBS Group AG, Granahan Investment Management Inc. MA, Artal Group S.A., and Parkman Healthcare Partners LLC. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bob D Brown, James B Weissman, Karen Blasing, Ling Zeng, Regina M Paglia, Robert D Ciappenelli, Shreeram Aradhye, and Stan Klimoff.
View insider buying and selling activity for Dicerna Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was purchased by a variety of institutional investors in the last quarter, including Commodore Capital LP, EcoR1 Capital LLC, Great Point Partners LLC, Assenagon Asset Management S.A., Morgan Stanley, Two Sigma Advisers LP, Two Sigma Investments LP, and Voloridge Investment Management LLC. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Douglas Fambrough, and Marc D Kozin.
View insider buying and selling activity for Dicerna Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $37.99.

How much money does Dicerna Pharmaceuticals make?

Dicerna Pharmaceuticals has a market capitalization of $2.96 billion and generates $164.31 million in revenue each year. The biopharmaceutical company earns $-112.75 million in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Dicerna Pharmaceuticals have?

Dicerna Pharmaceuticals employs 302 workers across the globe.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Where are Dicerna Pharmaceuticals' headquarters?

Dicerna Pharmaceuticals is headquartered at 33 HAYDEN AVENUE, LEXINGTON MA, 02421.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at (617) 621-8097, via email at [email protected], or via fax at 617-612-6298.

This page was last updated on 11/29/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.